Economic evaluation of the cardiac insufficiency bisoprolol study for the federal republic of Germany

PharmacoEconomics

Volumn 13, Issue 1 PART II, 1998, Pages 147-155

  Schädlich, Peter K ^a  

^a MERCK KGAA   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; BISOPROLOL FUMARATE; CALCIUM ANTAGONIST; DIGITALIS GLYCOSIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; VASODILATOR AGENT;

ARTICLE; COST BENEFIT ANALYSIS; COST CONTROL; DRUG COST; ECONOMIC EVALUATION; HEALTH INSURANCE; HEART FAILURE; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL;

ADRENERGIC BETA-ANTAGONISTS; BISOPROLOL; COSTS AND COST ANALYSIS; GERMANY; HEART FAILURE, CONGESTIVE; HUMANS;

EID: 0031983907     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-199813010-00014     Document Type: Article

References (2)

1. Cohn JN. Current therapy of failing heart. Circulation 1988; 78: 1099-107
2. Peters DH, Benfield P. Metoprolol: a pharmacoeconomic and quality-of-Iife evaluation of its use in hypertension, post-myocardial infarction and dilated cardiomyopathy. Pharmacoeconomics 1994; 6: 370-400